1
|
Prajapati SC, Chauhan SS. Dipeptidyl peptidase III: a multifaceted oligopeptide N-end cutter. FEBS J 2011; 278:3256-76. [DOI: 10.1111/j.1742-4658.2011.08275.x] [Citation(s) in RCA: 60] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
|
2
|
Calabrese EJ. Hormetic Dose-Response Relationships in Immunology: Occurrence, Quantitative Features of the Dose Response, Mechanistic Foundations, and Clinical Implications. Crit Rev Toxicol 2008; 35:89-295. [PMID: 15839378 DOI: 10.1080/10408440590917044] [Citation(s) in RCA: 91] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
This article provides an assessment of the occurrence of immune-system-related hormetic-like biphasic dose-response relationships. Such dose-response relationships are extensive, with over 90 different immune response-related endpoints reported, induced by over 70 endogenous agonists, over 100 drugs, and over 40 environmental contaminants. Such hormetic responses were reported in over 30 animal models, over a dozen mammalian and human cell lines. These findings demonstrate that immune-system-related hormetic-like biphasic dose-response relationships are common and highly generalizable according to model, endpoint, and chemical class. The quantitative features of the dose response are generally consistent with previously published examples of hormetic dose responses for other biological endpoints. These findings were generally recognized and explicitly discussed by the original authors, often with consideration given to possible mechanistic foundations as well as numerous clinical implications. Despite the recognition by individual authors of the hormetic nature of these observed responses, the overall widespread nature of immune-related hormetic responses has been only little appreciated, with a general lack of insight into the highly generalizable nature of this phenomenon as well as the complex regulatory networks affecting biological switching mechanisms that result in the hormetic responses.
Collapse
Affiliation(s)
- Edward J Calabrese
- Environmental Health and Health Sciences, University of Massachusetts, Amherst, Massachusetts 01003, USA.
| |
Collapse
|
3
|
Jenny M, Winkler C, Spetea M, Schennach H, Schmidhammer H, Fuchs D. Non-peptidic delta-opioid receptor antagonists suppress mitogen-induced tryptophan degradation in peripheral blood mononuclear cells in vitro. Immunol Lett 2008; 118:82-7. [PMID: 18440650 DOI: 10.1016/j.imlet.2008.03.006] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2008] [Revised: 03/14/2008] [Accepted: 03/14/2008] [Indexed: 10/22/2022]
Abstract
Opioid receptors are expressed not only on neuroendocrine cells but also on immunocompetent cells such as lymphocytes, monocytes and macrophages. micro-Opioid receptor agonists were found to exert immunosuppressive effects, whereas delta-opioid receptor agonists have been shown to act as immunostimulants. delta-Opioid receptor agonists stimulate T and B cells and activate granulocytes and monocytes, conversely, immunostimulation can be blocked by the non-peptidic delta-opioid receptor antagonist (NTI). We investigated the impact of NTI and of the two structurally related compounds HS-378 and HS-459 on degradation of tryptophan and formation of neopterin in mitogen-stimulated human peripheral blood mononuclear cells (PBMC). Both these biochemical pathways were found to be suppressed by all three opioid receptor antagonists, HS-378 and HS-459 exhibiting slightly greater potency than NTI. The suppression of tryptophan degradation suggests that the tested delta-opioid antagonists are able to influence the serotonergic system via a non-opioid action.
Collapse
Affiliation(s)
- Marcel Jenny
- Division of Biological Chemistry, Biocenter, Innsbruck Medical University, Innsbruck, Austria
| | | | | | | | | | | |
Collapse
|
4
|
Aceto MD, May EL, Harris LS, Bowman ER, Cook CD. Pharmacological studies with a nonpeptidic, delta-opioid (-)-(1R,5R,9R)-5,9-dimethyl-2'-hydroxy-2-(6-hydroxyhexyl)-6,7-benzomorphan hydrochloride ((-)-NIH 11082). Eur J Pharmacol 2007; 566:88-93. [PMID: 17434480 PMCID: PMC2994320 DOI: 10.1016/j.ejphar.2007.03.008] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2006] [Revised: 02/28/2007] [Accepted: 03/06/2007] [Indexed: 11/25/2022]
Abstract
In the search for a selective delta-opioid receptor agonist, (-)-(1R,5R,9R)-5,9-dimethyl-2'-hydroxy-2-(6-hydroxyhexyl)-6,7-benzomorphan hydrochloride ((-)-NIH 11082) and the (+)-enantiomer were synthesized and tested. (-)-NIH 11082 displayed antinociceptive activity in the paraphenylquinone test (PPQ test) in male ICR mice [ED50=1.9 (0.7-5.3) mg/kg, s.c.] and showed little, if any, activity in the tail-flick and hot-plate assays. The (+)-enantiomer was essentially inactive indicating stereoselectivity. Opioid receptor subtype characterization studies indicated that naltrindole, a delta-opioid receptor antagonist, was potent versus the ED80 of (-)-NIH 11082 in the PPQ test [AD50=0.75 (0.26-2.20) mg/kg, s.c]. beta-Funaltrexamine and nor-binaltorphimine, selective mu- and kappa-receptor antagonists, respectively, were inactive versus the ED80 of (-)-NIH 11082. In rats with inflammation-induced pain, (-)-NIH 11082 produced antihyperalgesic effects that were attenuated by naltrindole. In morphine-dependent rhesus monkeys of both sexes, (-)-NIH 11082 neither substituted for morphine nor exacerbated withdrawal signs in the dose range of 4.0 to 32.0 mg/kg, s.c. Neither convulsions nor other overt behavioral signs were observed in any of the species tested. The results indicate that (-)-NIH 11082 has delta-opioid receptor properties.
Collapse
Affiliation(s)
- Mario D Aceto
- Department of Pharmacology and Toxicology, School of Medicine, Virginia Commonwealth University, Richmond, VA 23298-0613, USA.
| | | | | | | | | |
Collapse
|
5
|
|
6
|
D'Ambrosio A, Noviello L, Negri L, Schmidhammer H, Quintieri F. Effect of novel non-peptidic delta opioid receptor antagonists on human T and B cell activation. Life Sci 2004; 75:63-75. [PMID: 15102522 DOI: 10.1016/j.lfs.2003.12.003] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2003] [Accepted: 12/03/2003] [Indexed: 10/26/2022]
Abstract
The effects of the antagonist naltrindole (NTI) on cells of the immune system have been largely studied although the mechanisms of action are still unclear. The aim of this study is to evaluate, in vitro, the immunomodulatory activity of four new delta-selective opioid compounds structurally related to naltrindole. The effects at different concentrations of these opioid antagonists on proliferative response were studied on normal human peripheral blood mononuclear cells (PBMC) stimulated with different stimuli: mitogens, the antigen PPD, the anti-CD3 monoclonal antibodies (mAb), the superantigen Staphylococcus aureus Cowan strain 1 (SAC) and alloantigens in the mixed lymphocyte cultures (MLR). The immunomodulatory capacity of these compounds was evaluated by determining the interleukin-2 (IL-2) release in mitogen activated PBMC. The present study shows that all the new delta opioid antagonists at 10(-5) M concentration are immunosuppressive. The inhibitory action is also evident at lower concentrations when anti-CD3 mAb and SAC were used as stimulators. In addition, the production of IL-2 was inhibited by the opioid treatment, but this might not be the only mechanism of action.
Collapse
Affiliation(s)
- Antonella D'Ambrosio
- Department of Immunology, Istituto Superiore di Sanità, V.le Regina Elena 299, 00161 Rome, Italy.
| | | | | | | | | |
Collapse
|
7
|
Grundt P, Martinez-Bermejo F, Lewis JW, Husbands SM. Opioid binding and in vitro profiles of a series of 4-hdroxy-3-methoxyindolomorphinans. Transformation of a delta-selective ligand into a high affinity kappa-selective ligand by introduction of a 5,14-substituted bridge. J Med Chem 2003; 46:3174-7. [PMID: 12825957 DOI: 10.1021/jm030801n] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
In investigation of the effects of 14-substitution in the indolomorphinan series of delta-selective opioid ligands, 5,14-bridged indolomorphinans (4) were prepared from the equivalent dihydrothebainone acid-catalyzed rearrangement products of the dihydrothevinols. Though the new ligands generally had low affinity for opioid receptors and no delta-selectivity, 4b had high kappa-affinity and substantial selectivity which was also seen in the precursor morphinanone (3b). This indicates that the methylbenzylidene-substituted bridge in these compounds is a dominant kappa-opioid receptor binding motif.
Collapse
Affiliation(s)
- Peter Grundt
- Department of Pharmacy and Pharmacology, University of Bath, Bath, BA2 7AY, UK
| | | | | | | |
Collapse
|
8
|
Narayan P, Pandey R, Yadav VS, Tandon R, Haq W, Dhar MM, Singh VK. Inhibition of anti-CD3 and interleukin-2 stimulated T lymphocyte proliferation by peptidomimetic opioid compound. Immunopharmacol Immunotoxicol 2003; 25:225-33. [PMID: 12784915 DOI: 10.1081/iph-120020472] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
In continuation to our earlier studies with peptidomimetic opioid compounds, we have further investigated immunosuppressive properties of one of our peptidomimetic compound (Tyr-NH-CH2-CH2-O-Phe-NH2) using peripheral blood mononuclear cells (PBMCs) of healthy volunteers. Peptidomimetic compound was evaluated for its effect on anti-CD3 and recombinant human interleukin-2 (rhIL-2) stimulated lymphocyte proliferation in vitro and lipopolysaccharide (LPS) induced activation of mitogen activated protein kinase (MAPK, pp42/44) in mouse macrophage cells (RAW 264.7). Our results show the immunosuppressive potential of synthetic peptidomimetic compound. This compound significantly inhibited anti-CD3 and rhIL-2 stimulated lymphocyte proliferation in vitro. However, this peptidomimetic compound did not show any effect on LPS induced MAPK activation. These observations suggest that above peptidomimetic compound has potential to inhibit immune responses mediated by lymphocytes.
Collapse
Affiliation(s)
- P Narayan
- Department of Immunology, Sanjay Gandhi Post-Graduate Institute of Medical Sciences, Lucknow, India
| | | | | | | | | | | | | |
Collapse
|
9
|
Grundt P, Jales AR, Traynor JR, Lewis JW, Husbands SM. 14-amino, 14-alkylamino, and 14-acylamino analogs of oxymorphindole. Differential effects on opioid receptor binding and functional profiles. J Med Chem 2003; 46:1563-6. [PMID: 12672258 DOI: 10.1021/jm021073r] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
The 14-amino analogue of oxymorphindole (OMI) was synthesized and found to possess delta-opioid binding affinity and selectivity similar to OMI. Substitution of the amino group with alkyl, arylalkyl, and acyl groups had relatively little effect on delta-affinity but delta-selectivity was reduced. In functional assays the 14-phenylacetylamino derivative 6d was a selective delta-agonist whereas the phenethylamino analogue 5d was a mu-agonist and low efficacy delta partial agonist that warrants further investigation as an analgesic with low tolerance and dependence.
Collapse
MESH Headings
- Analgesics, Opioid/chemical synthesis
- Analgesics, Opioid/chemistry
- Analgesics, Opioid/pharmacology
- Animals
- Binding, Competitive
- CHO Cells
- Cricetinae
- Morpholines/chemical synthesis
- Morpholines/chemistry
- Morpholines/pharmacology
- Radioligand Assay
- Receptors, Opioid, delta/agonists
- Receptors, Opioid, delta/metabolism
- Receptors, Opioid, mu/agonists
- Receptors, Opioid, mu/metabolism
- Structure-Activity Relationship
Collapse
Affiliation(s)
- Peter Grundt
- Department of Pharmacy and Pharmacology, University of Bath, UK
| | | | | | | | | |
Collapse
|
10
|
Abstract
Opioid analgesics provide outstanding benefits for relief of severe pain. The mechanisms of the analgesia accompanied with some side effects have been investigated by many scientists to shed light on the complex biological processes at the molecular level. New opioid drugs and therapies with more desirable properties can be developed on the bases of accurate insight of the opioid ligand-receptor interaction and clear knowledge of the pharmacological behavior of opioid receptors and the associated proteins. Toward this goal, recent advances in selective opioid receptor agonists and antagonists including opioid ligand-receptor interactions are summarized in this review article.
Collapse
Affiliation(s)
- Masakatsu Eguchi
- Pacific Northwest Research Institute, 720 Broadway, Seattle, Washington 98122, USA.
| |
Collapse
|
11
|
Schütz J, Dersch CM, Horel R, Spetea M, Koch M, Meditz R, Greiner E, Rothman RB, Schmidhammer H. Synthesis and biological evaluation of 14-alkoxymorphinans. 17. Highly delta opioid receptor selective 14-alkoxy-substituted indolo- and benzofuromorphinans. J Med Chem 2002; 45:5378-83. [PMID: 12431065 DOI: 10.1021/jm020940p] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
14-Alkoxy analogues of naltrindole and naltriben differently substituted in positions 5 and 17 and at the indole nitrogen (compounds 28-44) have been synthesized in an effort to enhance the delta potency and/or delta selectivity and in order to further elaborate on structure-activity relationships of this class of compounds. Introduction of a 14-alkoxy instead of the 14-hydroxy group present in naltrindole resulted in somewhat lower delta binding affinity, while in many cases (compounds 31, 34, 37, 40, 41, 44, HS 378) the delta receptor selectivity was considerably increased. An ethoxy group in position 14 is superior to other alkoxy groups concerning delta affinity and selectivity (34, 41, 42, 44, HS 378). In [35S]GTP gamma S binding, compounds 34, 41, and HS 378 exhibited about one-tenth the antagonist potency of naltrindole at delta opioid receptors while their delta antagonist selectivity was considerably higher. 17-Methyl-substituted compounds 35 and 44 were found to be pure delta receptor agonists in this test.
Collapse
Affiliation(s)
- Johannes Schütz
- Department of Pharmaceutical Chemistry, Institute of Pharmacy, University of Innsbruck, Innrain 52a, A-6020 Innsbruck, Austria
| | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Kirst A, Wack C, Lutz WK, Eggert A, Kämpgen E, Fischer WH. Expression of functional kappa-opioid receptors on murine dendritic cells. Immunol Lett 2002; 84:41-8. [PMID: 12161282 DOI: 10.1016/s0165-2478(02)00128-1] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Endogenous and exogenous opioids are known to exert direct effects on the immune system and the expression of functional opioid receptors has been reported for several immune cell types. Since dendritic cells are important inducers and regulators of immune responses, we investigated whether murine dendritic cells express functional kappa-opioid receptors. FACScan analysis and radioligand binding studies revealed the expression of kappa-opioid receptors by murine dendritic cells, which by RT-PCR were also shown to express kappa-opioid mRNA. In a primary allogenic mixed-lymphocyte reaction the kappa-agonists dynorphin A and U50488H suppressed the capacity of dendritic cells to induce T-cell proliferation in a concentration-dependent manner. Preincubation with the kappa-specific antagonist nor-binaltrophimine abolished the observed effect, indicating specificity. In contrast, antigen uptake by dendritic cells as well as phenotypic maturation of dendritic cells were not influenced by the kappa-agonists dynorphin A and U50488H. In summary our data demonstrate that dendritic cells express functional kappa-opioid receptors and that specific agonists exert a direct effect on these cells. Therefore, dendritic cells might be involved in the interaction of the neuroendocrine hormones and the immune system.
Collapse
MESH Headings
- 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer/pharmacology
- Animals
- Antigen Presentation/drug effects
- Dendritic Cells/drug effects
- Dendritic Cells/immunology
- Dendritic Cells/metabolism
- Dynorphins/pharmacology
- Gene Expression/drug effects
- Histocompatibility Antigens Class II/metabolism
- In Vitro Techniques
- Mice
- Mice, Inbred BALB C
- Mice, Inbred C57BL
- Naltrexone/analogs & derivatives
- Naltrexone/pharmacology
- Narcotic Antagonists/pharmacology
- Neuroimmunomodulation/drug effects
- Phenotype
- RNA, Messenger/genetics
- RNA, Messenger/metabolism
- Receptors, Opioid, kappa/agonists
- Receptors, Opioid, kappa/genetics
- Receptors, Opioid, kappa/metabolism
Collapse
Affiliation(s)
- Annette Kirst
- Institute of Pharmacology and Toxicology, Julius-Maximilians-University, Versbacher Strasse 9, D-97078, Wurzburg, Germany
| | | | | | | | | | | |
Collapse
|
13
|
Narayan P, Tandon R, Haq W, Dhar MM, Singh VK. Inhibition of antigen specific lymphocyte proliferation and cytokine stimulation by peptidomimetic opioid compound. Int Immunopharmacol 2002; 2:751-7. [PMID: 12095165 DOI: 10.1016/s1567-5769(02)00011-5] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
In sequel to our preliminary observations with peptidomimetic opioid compounds, we have further investigated immunomodulatory activity of one peptidomimetic compound (Tyr-NH-CH2-CH2-O-Phe-NH2) with peripheral blood mononuclear cells (PBMCs) of healthy volunteers/tuberculosis patients. This peptidomimetic compound was evaluated for its effect on purified protein derivative (PPD) stimulated lymphocyte proliferation in vitro, production of Th1 and Th2 cytokines by ELISA and ribonuclease protection assay. Our study shows the immunosuppressive potential of above synthetic peptidomimetic compound. This compound inhibited PPD stimulated human lymphocyte proliferation and this inhibition was reversed by opioid receptor antagonist, naloxone. Its immunosuppressive effect was further demonstrated by inhibition of interleukin-9 (IL-9), IL-10 but failed to influence IL-2, IL-15 and interferon-y (IFN-gamma) in PPD stimulated human PBMCs.
Collapse
Affiliation(s)
- P Narayan
- Department of Immunology, Sanjay Gandhi Post-Graduate Institute of Medical Sciences, Lucknow, India
| | | | | | | | | |
Collapse
|
14
|
Bergasa NV, Liau S, Homel P, Ghali V. Hepatic Met-enkephalin immunoreactivity is enhanced in primary biliary cirrhosis. LIVER 2002; 22:107-13. [PMID: 12028403 DOI: 10.1034/j.1600-0676.2002.01458.x] [Citation(s) in RCA: 54] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
BACKGROUND/AIMS In contrast to the normal adult liver, the fetal human and rat livers, and the liver of rats with cholestasis secondary to bile duct resection (BDR) express the preproenkephalin (ppENK) mRNA, which codes for the endogenous opioid peptide Met-enkephalin. In addition, Met-enkephalin immunoreactivity (MEIR) is detected in hepatocytes and in proliferating bile ductules in the cholestatic rat liver. These data suggest that cholestasis is associated with the resurgence of cells that produce Met-enkephalin. To explore further the status of opioids in cholestasis, we studied the expression of MEIR in liver tissue. METHODS The MEIR was sought in paraffin-preserved liver tissues from patients with primary biliary cirrhosis (PBC) (n = 10). RESULTS The MEIR was detected in all the PBC livers. Its intensity varied from weak to strong on hepatocytes and bile ducts and the strongest expression appeared as coarse granules. The MEIR was either absent or only faintly expressed by some hepatocytes from disease and nondisease control biopsies, but absent from bile ducts. CONCLUSION These results suggest that the human liver in cholestasis may be a source of endogenous opioids.
Collapse
Affiliation(s)
- Nora V Bergasa
- Division of Gastroenterology and Liver Disease, Beth Israel Medical Center, New York, USA.
| | | | | | | |
Collapse
|
15
|
Srivastava SK, Husbands SM, Aceto MD, Miller CN, Traynor JR, Lewis JW. 4'-Arylpyrrolomorphinans: effect of a pyrrolo-N-benzyl substituent in enhancing delta-opioid antagonist activity. J Med Chem 2002; 45:537-40. [PMID: 11784158 DOI: 10.1021/jm010841w] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
A new method for the preparation of N-benzylpyrrolomorphinans has been developed. Thus Michael reaction of the benzylimines of oxycodones and oxymorphones with nitrostyrenes gave a series of 4'-aryl-N-benzylpyrrolomorphinans. These were selective delta antagonists of much higher in vitro potency (with 5a having K(e) delta = <1 nM) than their binding affinities predicted. In mice in vivo assays 5a showed good delta antagonist activity in the anti-writhing analgesic assay and also inhibited delta agonist-induced convulsant activity.
Collapse
|
16
|
Bourrel F, Massou S, Baltas M, Bergon M, Tafani M, Esquere JP, Tisnès P, Prigent Y. Synthesis, NMR characterization and pharmacological evaluation of ligands derived from diprenorphine for central opioid receptors imaging. J PHYS ORG CHEM 2001. [DOI: 10.1002/poc.423] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
17
|
Narayan P, Singh VK, Agarwal SS, Tandon R, Haq W, Raghubir R, Dhar MM. Immunomodulation by opioid peptidomimetic compound. Neuroimmunomodulation 2001; 9:134-40. [PMID: 11752886 DOI: 10.1159/000049017] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
OBJECTIVE As a follow-up to our earlier studies on immunomodulation with opioid peptides, we synthesized and evaluated immunomodulatory activity of four peptidomimetic compounds, i.e. Tyr-NH-C(Me)(2)-CH(2)-O-Phe-NH(2 )(1), Tyr-NH-C(6)H(5)-(o)-CH(2)-CH(2)-O-Phe-NH(2) (2), Tyr-NH-CH(2)-CH(2)-O-Phe-NH(2) (3) and Tyr-NH-CH(D-Et)-CH(2)-O-Phe-NH(2) (4). METHODS These compounds were synthesized in solution phase and evaluated for their immunomodulatory properties in vitro by mixed lymphocyte reaction (MLR), proliferation of opioid receptor-expressing cells, production of tumor necrosis factor-alpha (TNF-alpha) and nitric oxide. RESULTS This study shows the immunosuppressive potential of synthetic peptidomimetic compound 3. This compound inhibited two-way MLR and suppressed the proliferation of the mu-opioid receptor expressing human embryonic kidney cells HEK 293 in vitro. Inhibition of MLR by compound 3 was reversed by naloxone (opioid receptor antagonist) and beta-funaltrexamine hydrochloride (mu-opioid receptor antagonist). The immunosuppressive effect of compound 3 was further demonstrated by inhibition of TNF-alpha and nitric oxide production in lipopolysaccharide-stimulated human PBMCs and mouse macrophage cells RAW 264.7, respectively. CONCLUSION These observations suggest that compound 3 inhibits MLR through mu-opioid receptor present on cells.
Collapse
MESH Headings
- Animals
- Cells, Cultured
- Humans
- Leukocytes, Mononuclear/drug effects
- Leukocytes, Mononuclear/immunology
- Leukocytes, Mononuclear/metabolism
- Macrophages/drug effects
- Macrophages/immunology
- Macrophages/metabolism
- Mice
- Naloxone/pharmacology
- Naltrexone/analogs & derivatives
- Naltrexone/pharmacology
- Narcotic Antagonists/pharmacology
- Neuroimmunomodulation/drug effects
- Neuroimmunomodulation/physiology
- Nitric Oxide/immunology
- Nitric Oxide/metabolism
- Opioid Peptides/immunology
- Opioid Peptides/metabolism
- Opioid Peptides/pharmacology
- Receptors, Opioid/drug effects
- Receptors, Opioid/immunology
- Receptors, Opioid/metabolism
- Receptors, Opioid, delta/drug effects
- Receptors, Opioid, delta/immunology
- Receptors, Opioid, delta/metabolism
- Receptors, Opioid, mu/drug effects
- Receptors, Opioid, mu/immunology
- Receptors, Opioid, mu/metabolism
- Tumor Necrosis Factor-alpha/drug effects
- Tumor Necrosis Factor-alpha/immunology
- Tumor Necrosis Factor-alpha/metabolism
Collapse
Affiliation(s)
- P Narayan
- Department of Immunology, Sanjay Gandhi Post-Graduate Institute of Medical Sciences, Lucknow, India
| | | | | | | | | | | | | |
Collapse
|
18
|
Abstract
BACKGROUND While genetically engineered viruses are now being tested for the virus therapy of human cancers, some naturally occurring viruses display unmatched oncolytic activity. Newcastle disease virus (NDV) excels as an oncolytic agent. OBJECTIVES As its virulence versus attenuation can be explained on molecular biological bases, it may be possible to develop or select highly oncolytic strains of NDV without adverse toxicity. STUDY DESIGN Questions are posed as to the mechanisms of viral oncolysis, the appropriateness of tests to predict oncolytic activity of a given NDV strain and the best modes of administration for oncolytic effects. Answers are provided based on specific data or on considerations drawn from experience (the authors use NDV oncolysates to immunize against melanoma and kidney carcinoma) or from analogous clinical situations (therapeutic use of mumps or measles viruses). RESULTS AND CONCLUSIONS NDV oncolysates probably suit better for immunotherapy (providing also active tumor-specific immunization) than massive repeated inoculations of NDV strains, especially when the NDV strain used is not proven to be oncolytic by appropriate pre-clinical tests.
Collapse
Affiliation(s)
- J G Sinkovics
- Cancer Institute, St. Joseph's Hospital, and The University of South Florida College of Medicine, Tampa 33607, USA.
| | | |
Collapse
|
19
|
Xu W, Huang LF, Bauer L, Bhargava HN, Dunn WJ. Synthesis and opiate receptor binding properties of 17-methyl-6,7-dehydro-3,14-dihydroxy-4,5alpha-epoxy-6,7:4',5'-pyrimidin omorphinans. Bioorg Med Chem Lett 1999; 9:3375-80. [PMID: 10612602 DOI: 10.1016/s0960-894x(99)00608-3] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
A class of opioid receptor active derivatives of oxymorphone has been synthesized using a common enaminone intermediate. The derivatives have heterocyclic groups fused to the 6,7-positions of the morphinan system and all were synthesized in high yield. A pyrazolo derivative is an agonist for the mu and delta receptors and an antagonist for the kappa receptor.
Collapse
Affiliation(s)
- W Xu
- College of Pharmacy, University of Illinois at Chicago, 60612-7231, USA
| | | | | | | | | |
Collapse
|
20
|
Bowden R, Tate SM, Soto S, Specter S. Alteration of cytokine levels in murine retrovirus infection: modulation by combination therapy. INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY 1999; 21:815-27. [PMID: 10606002 DOI: 10.1016/s0192-0561(99)00051-x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Immunoregulatory cytokines may regulate the resistance or susceptibility of a host to retroviral infection. These cytokines may be therapeutically modulated to prevent or limit the progression of infection. The non-progression to AIDS of some HIV+ patients has been related to a strong type 1 cytokine response (IL-2, IL-12, and IFNgamma). For this reason, we investigated the ability of combination therapeutics to modulate cytokines in vivo towards a type 1 cytokine response in a murine retroviral infection using Friend leukemia virus (FLV). BALB/c mice were infected with FLV and treated with either 3'-azido-3'-deoxythymidine (AZT), the immunomodulator methionine enkephalin (MENK), or a combination of both AZT and MENK starting 3 d post infection. Splenocytes were harvested on days 1, 3, 7, 14, 21 and 28 post treatment initiation and cultured with 1 microg/ml concanavalin A (ConA) for 24 h. Supernatants were examined for IL-2, IL-4, IL-10, IL-12, and IFNgamma cytokine production using cytokine specific ELISAs. The levels of type 2 cytokines were not significantly changed by any treatment group over the course of the disease. However, although decreased in all infected animals, type 1 cytokines were partially maintained by the combination treatment through day 21. RT-PCR for cytokine specific mRNA confirmed these results, with expression of the type 1 cytokines, especially IFNgamma, being maintained through day 21. Establishment of a treatment regime that can maintain protective cytokine activities against disease progression may prove applicable to other retroviral infections.
Collapse
MESH Headings
- Adjuvants, Immunologic/therapeutic use
- Animals
- Antimetabolites, Antineoplastic/therapeutic use
- Combined Modality Therapy
- Cytokines/biosynthesis
- Cytokines/blood
- Cytokines/genetics
- Enkephalin, Methionine/therapeutic use
- Enzyme-Linked Immunosorbent Assay
- Female
- Friend murine leukemia virus
- Gene Expression Regulation, Leukemic/drug effects
- Gene Expression Regulation, Viral/drug effects
- Leukemia, Experimental/blood
- Leukemia, Experimental/drug therapy
- Leukemia, Experimental/therapy
- Mice
- Mice, Inbred BALB C
- Neoplasm Proteins/biosynthesis
- Neoplasm Proteins/blood
- Neoplasm Proteins/genetics
- RNA, Messenger/biosynthesis
- RNA, Messenger/genetics
- RNA, Neoplasm/biosynthesis
- RNA, Neoplasm/genetics
- Retroviridae Infections/blood
- Retroviridae Infections/drug therapy
- Retroviridae Infections/therapy
- Reverse Transcriptase Polymerase Chain Reaction
- Specific Pathogen-Free Organisms
- Spleen/pathology
- Th1 Cells/metabolism
- Th2 Cells/metabolism
- Tumor Virus Infections/blood
- Tumor Virus Infections/drug therapy
- Tumor Virus Infections/therapy
- Zidovudine/therapeutic use
Collapse
Affiliation(s)
- R Bowden
- Department of Medical Microbiology and Immunology, University of South Florida College of Medicine, Tampa 33612, USA
| | | | | | | |
Collapse
|
21
|
Singh VK, Bajpai K, Narayan P, Yadav VS, Dhawan VC, Haq W, Mathur KB, Agarwal SS. Delta-opioid receptor antagonist inhibits immunomodulation by Met-enkephalin analogs. Neuroimmunomodulation 1999; 6:355-60. [PMID: 10474054 DOI: 10.1159/000026395] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
The methionine-enkephalin (Met-enkephalin, Tyr-Gly- Gly-Phe-Met) analogs Tyr-D-Ala-Gly-MePhe-Met NHC(3)H(7)-iso (1) and Tyr-D-Ala-Gly-MePhe-Gly-NHC(3)H(7)-iso (2) have been shown to enhance human T cell proliferation in in vitro treatment. Their immunomodulatory activities were completely blocked by naloxone, an opioid antagonist. Now we demonstrate that a selective delta-opioid receptor antagonist, ICI-174,864, completely blocks enhancement of T cell proliferation by analogs (1) and (2). The T cell-stimulatory effect was only partially inhibited by the mu-receptor-selective antagonist, beta-funaltrexamine hydrochloride. The kappa-opioid receptor antagonist, nor-binaltorphimine dihydrochloride, showed no effect on T cell-proliferation stimulated by analogs (1) and (2). These observations suggest that analogs (1) and (2) of Met-enkephalin stimulate T cell proliferation predominantly via delta-opioid receptor present on T cells.
Collapse
Affiliation(s)
- V K Singh
- Department of Immunology, Sanjay Gandhi Post-Graduate Institute of Medical Sciences, Lucknow, India.
| | | | | | | | | | | | | | | |
Collapse
|
22
|
Coop A, Rothman RB, Dersch C, Partilla J, Porreca F, Davis P, Jacobson AE, Rice KC. delta Opioid affinity and selectivity of 4-hydroxy-3-methoxyindolomorphinan analogues related to naltrindole. J Med Chem 1999; 42:1673-9. [PMID: 10229636 DOI: 10.1021/jm9807003] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
To investigate the effect of the introduction of a 4-phenolic substituent on the delta opioid affinity and selectivity of the indolomorphinans, a range of 4-phenolic analogues of naltrindole were prepared and evaluated in in vitro assays. Although the majority of the ligands displayed poor affinity for all three opioid receptors (mu, kappa, delta), 17-cyclopropylmethyl-6, 7-didehydro-4-hydroxy-3-methoxy-6,7:2',3'-indolomorphinan (13) was an exception, displaying excellent delta binding selectivity (delta Ki = 7 nM, mu/delta = 1900, mu/kappa = 1130). GTP-gamma-S functional assays showed 13 to be a selective delta antagonist, albeit with lower potency than naltrindole. Although the reason for the unique profile of 13 could not be determined, these results validate our approach of introducing groups into the indolomorphinans that are known to reduce mu activity, to obtain increased delta selectivity.
Collapse
Affiliation(s)
- A Coop
- Laboratory of Medicinal Chemistry, Building 8, Room B1-23, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
| | | | | | | | | | | | | | | |
Collapse
|
23
|
Abstract
The deltorphins are a class of highly selective delta-opioid heptapeptides from the skin of the Amazonian frogs Phyllomedusa sauvagei and P. bicolor. The first of these fascinating peptides came to light in 1987 by cloning of the cDNA of from frog skins, while the other members of this family were identified either by cDNA or isolation of the peptides. The distinctive feature of deltorphins is the presence of a naturally occurring D-enantiomer at the second position in their common N-terminal sequence, Tyr-D-Xaa-Phe, comparable to dermorphin, which is the prototype of a group of mu-selective opioids from the same source. The D-amino acid and the anionic residues, either Glu or Asp, as well as their unique amino acid compositions are responsible for the remarkable biostability, high delta-receptor affinity, bioactivity and peptide conformation. This review summarizes a decade of research from many laboratories that defined which residues and substituents in the deltorphins interact with the delta-receptor and characterized pharmacological and physiological activities in vitro and in vivo. It begins with a historical description of the topic and presents general schema for the synthesis of peptide analogues of deltorphins A, B and C as a means to document the methods employed in producing a myriad of analogues. Structure activity studies of the peptides and their pharmacological activities in vitro are detailed in abundantly tabulated data. A brief compendium of the current level of knowledge of the delta-receptor assists the reader to appreciate the rationale for the design of these analogues. Discussion of the conformation of these peptides addresses how structure leads to further hypotheses regarding ligand receptor interaction. The review ends with a broad discussion of the potential applications of these peptides in clinical and therapeutic settings.
Collapse
Affiliation(s)
- L H Lazarus
- Peptide Neurochemistry, National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709, USA
| | | | | | | |
Collapse
|
24
|
Biswas S, Singh VK, Rastogi A, Sharan R, Haq W, Mathur KB, Agarwal SS. Stimulation of IL-2 production and CD2R expression by splenopentin analogs. INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY 1997; 19:341-5. [PMID: 9467753 DOI: 10.1016/s0192-0561(97)00032-5] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Splenopentin (SP-5), is a pentapeptide corresponding to the amino acid sequence 32-36 (Arg-Lys-Glu-Val-Tyr) of the splenic hormone splenin. Its synthetic analogs: Lys-Lys-Glu-Val-Tyr(1) and D-Lys-Lys-Glu-Val-Tyr (2) have been evaluated for active T-cell rosette (CD2R), total T-cell rosette (CD2), interleukin-2 (IL-2) stimulation and effect on antibody production. SP-5 as well as both the analogs stimulated CD2R. Analogs (1) and (2) were also found to stimulate IL-2 production. These observations suggest that in vitro human NK cell augmentation with analogs (1) and (2) reported earlier may be due to enhanced IL-2 production.
Collapse
Affiliation(s)
- S Biswas
- Department of Immunology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India
| | | | | | | | | | | | | |
Collapse
|
25
|
House RV, Thomas PT, Bhargava HN. In vitro exposure to peptidic delta opioid receptor antagonists results in limited immunosuppression. Neuropeptides 1997; 31:89-93. [PMID: 9574844 DOI: 10.1016/s0143-4179(97)90026-3] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Previous studies by our group have demonstrated that in vitro exposure to delta-opioid receptor agonists results in a significant immunostimulation, whereas in vitro exposure to non-peptidic delta-opioid receptor antagonists results in significant suppression of various immune functions. The present study assessed potential immunomodulation by the peptidic delta-opioid receptor antagonists TIPP, D-TIPP, and ICI 174864 using a panel of in vitro immune function assays. Splenocytes from female B6C3F1 mice were cultured with the peptides at concentrations of 0.00001-10 microM. B cell proliferation was quantified following cellular activation, T cell function was assessed by cytokine production following stimulation with anti-CD3 monoclonal antibody, natural immunity was assessed by quantitating natural killer (NK) cell activity following a 24-h exposure, and macrophage function was assessed by quantification of interleukin-6 (IL-6) production. None of the peptides examined significantly affected B cell proliferation. Production of IL-2 by T cells was not consistently affected by exposure to either TIPP or D-TIPP, but was significantly suppressed at 10 microM ICI 174864. Production of IL-4, however, was significantly suppressed by low concentrations of either TIPP or D-TIPP, and by 10 microM ICI 174864. IL-6 production by macrophages was unaffected except for sporadic incidents of enhanced production in cells exposed to ICI 174864. NK cell function exhibited a differential pattern of suppression, with the greatest degree of suppression observed following exposure to TIPP and only slight suppression in cells exposed to either D-TIPP or ICI 174864. These data suggest that peptidic delta-opioid receptor antagonists do not exhibit the same pattern or degree of immunosuppressive activity as the non-peptidic antagonists at equivalent in vitro concentrations.
Collapse
MESH Headings
- Animals
- B-Lymphocytes/chemistry
- B-Lymphocytes/cytology
- B-Lymphocytes/immunology
- Cell Division/drug effects
- Cell Division/immunology
- Enkephalin, Leucine/analogs & derivatives
- Enkephalin, Leucine/pharmacology
- Female
- Immune Tolerance/drug effects
- Immune Tolerance/immunology
- Interleukin-2/metabolism
- Interleukin-6/metabolism
- Killer Cells, Natural/chemistry
- Killer Cells, Natural/immunology
- Macrophages/chemistry
- Macrophages/immunology
- Macrophages/metabolism
- Mice
- Mice, Inbred C3H
- Mice, Inbred C57BL
- Narcotic Antagonists/pharmacology
- Oligopeptides/pharmacology
- Receptors, Opioid, delta/antagonists & inhibitors
- Receptors, Opioid, delta/immunology
- T-Lymphocytes/chemistry
- T-Lymphocytes/immunology
- T-Lymphocytes/metabolism
- Tetrahydroisoquinolines
Collapse
Affiliation(s)
- R V House
- Life Sciences Department, IIT Research Institute, Chicago, IL 60616, USA.
| | | | | |
Collapse
|
26
|
Bajpai K, Singh VK, Dhawan VC, Haq W, Mathur KB, Agarwal SS. Immunomodulation by two potent analogs of met-enkephalin. IMMUNOPHARMACOLOGY 1997; 35:213-20. [PMID: 9043934 DOI: 10.1016/s0162-3109(96)00147-6] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Met-enkephalin (Tyr-Gly-Gly-Phe-Met) and its more stable analogs, Tyr-D-Ala-Gly-MePhe-Met-NHC3H gamma-iso (1) and Tyr-D-Ala-Gly-MePhe-Gly-NHC3H gamma-iso (2) significantly enhanced human T-cell proliferation in vitro after 5 days of incubation in the absence of mitogen. The activity was completely inhibited by naloxone, an opioid antagonist. These peptides significantly enhanced human active T-cell rosette (CD2R) also on in vitro treatment. Furthermore, these analogs stimulated interleukin-2 production by human peripheral blood mononuclear cells in vitro which was completely inhibited by naloxone. These observations suggest that human T-cells bear receptors for Met-enkephalin on their surface. Such findings may provide a link between the central nervous system and the immune system.
Collapse
Affiliation(s)
- K Bajpai
- Department of Immunology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India
| | | | | | | | | | | |
Collapse
|
27
|
Sin JI, Plotnikoff N, Specter S. Anti-retroviral activity of methionine enkephalin and AZT in a murine cell culture. INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY 1996; 18:305-9. [PMID: 8933209 DOI: 10.1016/0192-0561(96)00033-1] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Previously, this laboratory has demonstrated that azidothymidine used in combination with methionine enkephalin, an opioid pentapeptide, was more effective than AZT alone in inhibiting disease progression due to murine retrovirus infections. In order to study the mechanism(s) by which Met-ENK mediates-antiviral effects, when used in combination with AZT in Friend leukemia virus infected mice, an in vitro focus forming assay was used. AZT at 1 ng/ml inhibited FLV replication by 30-50% in the susceptible Mus dunni cell line. By contrast, the immunostimulatory neuropeptide, Met-ENK, displayed no direct inhibition of viral replication. This suggests that Met-ENK does not have any direct anti-retroviral activity. Subsequent testing of Met-ENK in the presence of AZT showed no ability of this peptide to promote inhibition of viral replication due to AZT. By contrast, in the presence of mouse spleen cells, as a source of lymphocytes, in vitro combination treatments using AZT and Met-ENK reduced FLV replication by 67%, compared to 47% using AZT alone. The inhibition due to Met-ENK was abrogated when spleen cells were pretreated with naloxone, an opioid antagonist. Therefore, we conclude that Met-ENK effects are mediated via opioid receptors on spleen cells and that the observed anti-FLV activity is dependent on the use of Met-ENK stimulated spleen cells in combination with AZT.
Collapse
Affiliation(s)
- J I Sin
- Department of Medical Microbiology and Immunology, University of South Florida, College of Medicine, Tampa 33612, USA
| | | | | |
Collapse
|
28
|
Morgan EL. Regulation of human B lymphocyte activation by opioid peptide hormones. Inhibition of IgG production by opioid receptor class (mu-, kappa-, and delta-) selective agonists. J Neuroimmunol 1996; 65:21-30. [PMID: 8642060 DOI: 10.1016/0165-5728(95)00171-9] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
Opioid peptides have been reported by many laboratories to modulate in vitro and in vivo cell-mediated and humoral immune responses. However, less attention has been afforded to the class or classes of opioid receptors involved in these immunomodulatory effects. Previous studies by this laboratory indicated that beta-endorphin and methionine-enkephalin were potent inhibitors of Staphylococcus aureus, Cowen strain I (SAC)-induced IgG production by human B lymphocytes. Results obtained from the present studies indicate that, at pharmacological concentrations, mu-, delta-, and kappa-receptor-selective agonists are potent inhibitors of SAC-induced IgG-secreting cells (IgG-ISC) by human B lymphocytes. Moreover, the suppression of IgG-ISC formation was reversed by mu-, delta-, and kappa-receptor class-selective antagonists, [D'Tic]cTAP, ICI 174,864, and nor-BNI, respectively. These findings are in agreement with other studies showing that more than one class of receptors are involved in opioid peptide-mediated immunoregulation. Additional studies indicated that all three class-selective receptor agonists were found to suppress SAC-induced IL-6 production in intact PBMC cultures. As observed for suppression of IgG-ISC formation, inhibition of IL-6 production was found to be reversed by the appropriate receptor class-selective antagonist. These results support the hypothesis that one mechanism of opioid peptide-mediated inhibition of antibody production is via the down regulation of cytokine synthesis.
Collapse
MESH Headings
- 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer
- Adult
- Analgesics/pharmacology
- B-Lymphocytes/chemistry
- B-Lymphocytes/immunology
- B-Lymphocytes/metabolism
- Enkephalin, Ala(2)-MePhe(4)-Gly(5)-
- Enkephalin, D-Penicillamine (2,5)-
- Enkephalins/pharmacology
- Female
- Humans
- Immunoglobulin G/metabolism
- Interleukin-6/metabolism
- Lymphocyte Activation/drug effects
- Lymphocyte Activation/immunology
- Male
- Opioid Peptides/pharmacology
- Pyrrolidines/pharmacology
- Receptors, Opioid/agonists
- Receptors, Opioid/immunology
- Receptors, Opioid/metabolism
- Receptors, Opioid, delta/agonists
- Receptors, Opioid, delta/immunology
- Receptors, Opioid, delta/metabolism
- Receptors, Opioid, kappa/agonists
- Receptors, Opioid, kappa/immunology
- Receptors, Opioid, kappa/metabolism
- Receptors, Opioid, mu/agonists
- Receptors, Opioid, mu/immunology
- Receptors, Opioid, mu/metabolism
- Staphylococcus aureus/immunology
Collapse
Affiliation(s)
- E L Morgan
- Department of Immunology, Scripps Research Institute, La Jolla, CA 92037, USA
| |
Collapse
|
29
|
House RV, Thomas PT, Bhargava HN. A comparative study of immunomodulation produced by in vitro exposure to delta opioid receptor agonist peptides. Peptides 1996; 17:75-81. [PMID: 8822513 DOI: 10.1016/0196-9781(95)02051-9] [Citation(s) in RCA: 39] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
The present study assessed the direct immunomodulatory effect of a panel of synthetic peptides exhibiting delta-opioid receptor agonist activity. Murine splenic lymphocytes and peritoneal macrophages were cultured in vitro with peptides at concentrations of 0.00001-10 microM. Assessment was made of B-cell function by quantitating cellular proliferation, T-cell function by measuring cytokine production, natural immunity by quantitating basal and cytokine-augmented natural killer (NK) cell activity, and macrophage function by production of IL-6. These peptides had minimal effects on B-cell proliferation at any concentration examined. In comparison, enhancement of cytokine production by T-helper cells occurred following exposure to several of the compounds, to a significant extent with DPDPE, DPDPE-trifluoroacetate, or deltorphin-1 and most pronounced at concentrations between 0.00001 and 0.1 microM. Likewise, IL-6 production by macrophages was significantly augmented by exposure to these three peptides. NK cell function was significantly enhanced by in vitro exposure to several of the peptides, with enhancement generally noted at concentrations between 0.00001 and 0.01 microM. However, some of the peptides (most notably DADLE) greatly suppressed NK cell activity. These data suggest that delta opioid agonists are broadly immunomostimulatory.
Collapse
MESH Headings
- Adjuvants, Immunologic/chemical synthesis
- Adjuvants, Immunologic/chemistry
- Adjuvants, Immunologic/pharmacology
- Amino Acid Sequence
- Animals
- B-Lymphocytes/drug effects
- B-Lymphocytes/immunology
- Cytokines/biosynthesis
- Enkephalins/chemical synthesis
- Enkephalins/chemistry
- Enkephalins/pharmacology
- Female
- In Vitro Techniques
- Interleukin-6/biosynthesis
- Killer Cells, Natural/drug effects
- Killer Cells, Natural/immunology
- Lymphocyte Activation/drug effects
- Macrophages, Peritoneal/drug effects
- Macrophages, Peritoneal/immunology
- Mice
- Molecular Sequence Data
- Oligopeptides/chemical synthesis
- Oligopeptides/chemistry
- Oligopeptides/pharmacology
- Receptors, Opioid, delta/agonists
- T-Lymphocytes, Helper-Inducer/drug effects
- T-Lymphocytes, Helper-Inducer/immunology
Collapse
Affiliation(s)
- R V House
- Life Sciences Department, IIT Research Institute, Chicago, IL 60616, USA
| | | | | |
Collapse
|
30
|
House RV, Thomas PT, Kozak JT, Bhargava HN. Suppression of immune function by non-peptidic delta opioid receptor antagonists. Neurosci Lett 1995; 198:119-22. [PMID: 8592635 DOI: 10.1016/0304-3940(95)11983-4] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Previous studies in this laboratory and elsewhere have provided evidence that compounds acting as delta opioid receptor agonists exhibit marked immunostimulatory potential. Conversely, the delta opioid receptor antagonists have previously been shown to demonstrate immunosuppressive effects as assessed by proliferation of T-cells following allogeneic or xenogeneic stimulation. The present study was performed to further characterize this immunosuppressive activity using the compounds benzylidene naltrexone (BNTX), naltrindole (NTI), and naltriben (NTB). In vitro exposure to BNTX resulted in an apparent dose-related suppression of B-cell proliferation, cytokine production by T-helper cells, and natural killer (NK) cell activity, with statistically significant suppression observed at concentrations between 1 and 10 microM. NTI was also immunosuppressive for all immune function parameters examined, although this compound was less active than BNTX. In vitro exposure to the structurally related compound NTB had no significant effect on any immune function examined in this study. In all cases, immunosuppression occurred in the absence of any detectable alteration in cellular viability, suggesting a specific immunosuppressive effect rather than overt toxicity.
Collapse
Affiliation(s)
- R V House
- Life Sciences Department, IIT Research Institute, Chicago, IL 60616-3799, USA
| | | | | | | |
Collapse
|
31
|
Gavériaux C, Peluso J, Simonin F, Laforet J, Kieffer B. Identification of kappa- and delta-opioid receptor transcripts in immune cells. FEBS Lett 1995; 369:272-6. [PMID: 7649271 DOI: 10.1016/0014-5793(95)00766-3] [Citation(s) in RCA: 112] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
To investigate the role of opioids as direct modulators of the immune response, we have searched for expression of the recently cloned delta, mu and kappa opioid receptors in immune cells. We have devised a reverse transcriptase-polymerase chain reaction strategy which specifically detects a region spanning putative transmembrane regions 2 to 7 for each transcript in both human and mouse immune cells. In human peripheral blood lymphocyte and monocyte preparations, delta was undetectable while the kappa transcript was present. The analysis of human cell lines revealed low but significant levels of delta opioid receptor transcripts in T, B or monocyte cell lines while the kappa transcript was found in B cell lines only. Investigation of murine cells showed the presence of transcript for the delta receptor in splenocytes and in some T and B cell lines. Unexpectedly, no expression of the mu receptor was detected. Sequence analysis of PCR products demonstrated nucleotide identity between immune and neuronal transcripts, indicating that they derive from the same genes. In conclusion, our results lead to the identification of kappa and delta opioid receptor transcripts in immune cells.
Collapse
MESH Headings
- Animals
- Base Sequence
- Brain/immunology
- Cell Line
- Cloning, Molecular
- Humans
- Leukocytes/metabolism
- Lymph Nodes/immunology
- Mice
- Molecular Sequence Data
- Polymerase Chain Reaction/methods
- RNA, Messenger/biosynthesis
- Receptors, Opioid, delta/biosynthesis
- Receptors, Opioid, delta/genetics
- Receptors, Opioid, kappa/biosynthesis
- Receptors, Opioid, kappa/genetics
- Sequence Analysis, DNA
- Spleen/immunology
- Tumor Cells, Cultured
Collapse
Affiliation(s)
- C Gavériaux
- Ecole Supérieure de Biotechnologie de Strasbourg, Illkirch, France
| | | | | | | | | |
Collapse
|
32
|
Bajpai K, Singh VK, Agarwal SS, Dhawan VC, Naqvi T, Haq W, Mathur KB. Immunomodulatory activity of met-enkephalin and its two potent analogs. INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY 1995; 17:207-12. [PMID: 7558515 DOI: 10.1016/0192-0561(94)00080-8] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
The effects of Met-enkephalin (Met-Enk), a delta receptor binding opioid peptide, and its more stable synthetic analogs, Tyr-D-Ala-Gly-MePhe-Met-NHC3H7-iso (1), Tyr-D-Ala-Gly-MePhe-Gly-NHC3H7-iso (2) and Tyr-D-Ala-Gly-MePhe-Gly-NHCH2C6H5 (3), on human T-cell transformation and natural killer (NK) cell cytotoxicity have been evaluated. Analogs 1 and 2 have been found to be as potent as Met-Enk in stimulating T-cell transformation and augmenting NK cell cytotoxicity. Analog 3 had no effect on T-cell transformation and NK cell cytotoxicity. Proliferative response was measured by 3H-thymidine uptake after 5 days of incubation. The kinetics of the T-cell transformation response (peak 5th day) is similar to those for in vitro T-cell responses to specific antigens rather than via polyclonal activation.
Collapse
Affiliation(s)
- K Bajpai
- Department of Immunology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India
| | | | | | | | | | | | | |
Collapse
|
33
|
Abstract
This paper is the sixteenth installment of our annual review of research concerning the opiate system. It is restricted to papers published during 1993 that concern the behavioral effects of the endogenous opiate peptides, and does not include papers dealing only with their analgesic properties. The specific topics this year include stress; tolerance and dependence; eating; drinking; gastrointestinal, renal, and hepatic function; mental illness and mood; learning, memory, and reward; cardiovascular responses; respiration and thermoregulation; seizures and other neurological disorders; electrical-related activity; general activity and locomotion; development; immunological responses; and other behaviors.
Collapse
Affiliation(s)
- G A Olson
- Department of Psychology, University of New Orleans, LA 70148
| | | | | |
Collapse
|